LISA Laser USA - RevoLix 200
by LISA Laser USA

Follow Us
DESCRIPTION

Excellent Hemostasis

The RevoLix 200 is the latest laser to be launched into the US market by Lisa Laser USA. The RevoLix 200 is the most advanced laser introduced for the treatment of BPH and is superior to all other laser technologies currently being used for the treatment of BPH. It has a wavelength of 2013 nm, which targets the water in the tissue, providing superior vaporization, cutting, and hemostasis of the prostate. There are many benefits to using the RevoLix 200, both for the surgeon and the patient.

Technique

With the RevoLix 200 the surgeon has the choice to vaporize, vapor – resect or resect tissue. This has the benefit of reducing the procedure time and the amount of time that the patient is anesthetized.

Visualization

The RevoLix 200 provides vastly superior visualization with no glare, which is important for the surgeon. Both the Holmium and Greenlight lasers provide poor hemostasis, allowing blood to impede the surgeon’s visualization.

Safety

The RevoLix 200 uses a laser wavelength that has strong absorption in water. This eliminates the risk of unintentional collateral damage to surrounding tissue.

Post Operative Pain

The RevoLix 200 uses a unique technology that produces a very shallow depth of necrosis. This means that there are less sloughing and consequently less post-operative pain. With the RevoLix 200, there is greater hemostasis than with other lasers which all result in a shorter catheterization time and a quicker recovery.

FORUMSView All
Ask a New Question

FEATURES

  • Consistent absorption by the chromophore
  • Narrow depth of thermal damage
  • Excellent hemostasis
  • Fast procedure times
  • Reusable and single-use 800 and 1000 micron fibers
  • Less postoperative pain
  • Less necrotic tissue generated
  • Faster patient turn around and recovery
  • Low cost per procedure due to reusable fibers
  • Utilization both in the Operating Room and the Office

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Please review our Privacy Policy for more details.
I Agree